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ABSTRACT
Objectives: In order to improve antimicrobial (AM)
use, a policy of providing technical and financial support
to AM management teams (AMTs) was rolled out in all
Belgian hospitals between 2002 and 2008. We aimed to
analyse the association of this policy with AM use for
the two indications accounting for the largest number of
patients receiving AM: prophylaxis for major lower limb
orthopaedic surgery and pneumonia.
Design, setting, participants: We used patient-level
data routinely collected in all Belgian acute care
hospitals between 1999 and 2010. We modelled trends
for selected quality indicators (QIs) using the year of
AMT implementation in each hospital as the main
‘change point’, with fine-tuned case-mix adjustment. Of
all admissions for lower limb orthopaedic surgery, and
pneumonia between 1999 and 2010, 90% (325 094)
and 95% (327 635), respectively, were found eligible for
analyses.
Outcomes: The surgery QI was defined as: cefazolin,
dose in the expected range, and no use of other AM. For
pneumonia, QIs were: ratio of oral/parenteral defined daily
doses (DDD, O/P QI), and mean number of DDD minus
penicillin, per 100 days of hospitalisation (DDD QI).
Results: Between 1999 and 2010, the surgery QI
improved from 59% to 71%, the O/P QI from 0.72 to 0.97,
and the DDD QI from 96 to 64. Heterogeneity between
hospitals was high. Overall, no association was found with
the year of implementation of the AMT.
Conclusions: Improvements have been observed but
could not be related at the national level to the policy under
study. However, these results cannot be extrapolated to
other QIs for AM use in hospitals. Our findings do not
question the need for AMT, nor the need for continuation of
AMT funding. Several recommendations can be made in
order to make the best of Belgium’s unique political and
financial commitments in that field.
INTRODUCTION
The inappropriate use of antimicrobials
(AM) and its consequences in terms of infec-
tions due to AM-resistant microorganisms
represents a major public health problem.1
Although the largest part of AM consumption
takes place in the community,2 the risks are
concentrated in hospitals: 35% of hospitalised
patients in Europe3 and 52% in the USA4 are
taking an AM. Over one-third of prescriptions
might not be compliant with evidence-based
guidelines.5 AM stewardship, conducted by AM
management teams (AMTs), is a key strategy to
improve AM prescribing, to ensure effective
treatment of patients and to reduce AM resist-
ance in hospitals.6 The need for a legal basis,
regulatory mechanisms and funding for AM
stewardship programmes and research are
widely endorsed.7 8
Belgium has been a pioneer in this ﬁeld.
The Belgian Antibiotic Policy Coordination
Strengths and limitations of this study
▪ First study to evaluate a national policy of imple-
menting and financing antimicrobial management
teams in hospitals with a longitudinal study design.
▪ Exhaustive database on all admissions in Belgian
hospitals over 11 years for the indications account-
ing for the largest number of patients receiving anti-
microbials in hospitals (antimicrobial prophylaxis
for lower limb orthopaedic surgery, pneumonia).
▪ Fine-tuned case-mix adjustment when comparing
hospitals before/after, and with/without the
policy, taking into account the possible time lag
between implementation and results.
▪ Quality indicators selected for this study
measure some important aspects of quality, but
fall short of providing a global picture of overall
quality of antimicrobial use in hospitals. This is
intrinsically complex, and other indicators might
provide different results.
▪ This study has shown no overall impact of the
policy on national trends, but has not investi-
gated the factors that determine success or
failure at hospital level.
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Committee (BAPCOC) was created in 1999 in order to
improve AM use in Belgium and has been very active
since then at different levels.9 Since July 2007, all acute
care hospitals in the country have been receiving ﬁnan-
cial and technical support for hiring a trained manager
for their AMT; the initiative was ﬁrst piloted in 37 volun-
tary hospitals (2002), then extended to another 24 hos-
pitals (2006), and ﬁnally to the remaining hospitals (55)
in 2007. Apart from funding, the intervention included
technical guidance and advanced specialist training for
the formal establishment and follow-up of AMTs.
However, hospitals were not given targets, and were left
to devise their own interventions and themes. A self-
reporting survey was conducted in 2007. Antibiotic stew-
ardship tools used by AMTs included (non-exhaustive
list): an antibiotic formulary (96% of hospitals), practice
guidelines for antibiotic therapy and surgical prophylaxis
(92%, and 96%, respectively), a list of restricted AM
agents (76%), sequential intravenous/oral therapy with
equivalent bioavailability (79%).10 The minimum com-
position, mandate and tasks of hospital AMT have a
legal basis since 2008. The largest part of the BAPCOC
budget now goes to stafﬁng and technical support for
AMT in all Belgian acute hospitals.9 To the best of our
knowledge, Belgium has been the ﬁrst country to
provide hospitals with structural, earmarked funding for
AMT, making the experience a test case for such a
policy.
The objectives of our study were to analyse the associ-
ation of this policy with trends of selected quality indica-
tors (QIs) for AM use in hospitals. We focused on the
indications accounting for the largest number of
patients receiving AM.
METHODS
Source of data and QIs
We obtained patient-level data routinely collected
between 1999 and 2010 in all Belgian acute care hospi-
tals for pathology-based ﬁnancing purposes. These
include the all-patient-reﬁned diagnosis-related group
(APR-DRG, V.15) and associated severity of illness (SoI,
1–4)11 as well as details on each AM used during the stay
(molecule, dose and route of administration); however,
the timing of AM administration is lacking. The SoI for
the hospital stay is assigned following a complex compu-
terised algorithm that takes into account the patient’s
primary and secondary diagnoses, procedures and age
(the underlying clinical principle is that patients with a
high SoI are characterised by multiple serious diseases
or illnesses).11
We used the WHO anatomical therapeutic chemical
(ATC)/deﬁned daily doses (DDD) method,12 applying
version WHO 2010 to all 12 years in the database.
Comparing hospitals (with or without the policy, as well
as before and after implementation of the policy) was
done per APR-DRG to facilitate case-mix adjustment.
The two APR-DRG with the highest number of patients
receiving AM were APR DRG 302 (major lower limb
orthopaedic surgery without trauma—mainly hip or
knee replacement—or revision) and APR DRG 139
(simple pneumonia). We decided against clinical
outcome measures such as mortality, readmission and
length of stay (LoS) because these are too indirectly
related to appropriate AM prescribing. Compliance with
guidelines for antibioprophylaxis in APR DRG 302
(‘surgery QI’) was deﬁned using three criteria at patient
level as: (1) choice of AM (cefazolin), dose in the
expected range (2–8 g) and (2) no other AM given
during the stay.13 We excluded from the analyses hos-
pital stays with secondary infectious diagnoses and SoI 3
and 4, so that it could fairly be assumed that there was
no other reason for prescribing an AM than antibiopro-
phylaxis. For pneumonia, the data did not allow asses-
sing the appropriateness of treatment at patient level. In
addition, treatment guidelines can differ between hospi-
tals. Aggregating data at hospital level, we selected two
QIs: (1) the ratio of oral DDD/parenteral DDD (‘O/P
QI’), as early parenteral to oral switch is recommended
to reduce LoS, adverse events related to intravenous
line, and costs13–15 and (2) total DDD ( J01) minus peni-
cillin ( J01C), per 100 days in hospital for pneumonia
(‘DDD QI’), under the assumption ‘less is better’.
Penicillin use was excluded because recommended daily
doses have increased over the years.
Statistical approach and adjustment for confounding
We used a change point model.16 Such a model tests
whether the slope of a trend is different before and
after the change point. We included as change points
the year each hospital received funding for its AMT
(2002, 2006, 2007), as well as the years 2001 (the year of
a very large awareness campaign for AM) and—for
pneumonia only—2006 (when a new ﬁnancing mechan-
ism for hospital drugs was introduced; however, this
mechanism did not apply to AM prophylaxis). We then
tested the need to include additional change points.
The surgery QI was a dichotomous variable at the
patient (stay) level, and variables adjusted for were LoS,
age (continuous), gender, SoI (1–2), and intensive care
unit (ICU) stay (at some point, hospitalised in the ICU).
For pneumonia, outcomes were continuous variables at
hospital level and required aggregation of patient (stay)
level data. Hospital variables for pneumonia stays were:
median LoS, distribution of the stays (%) according to
SoI (1–4), gender, ICU stay, patient origin at admission
(home, long-term care facility, other or unknown), dis-
charge status (dead/alive), and age categories (<1, 1–5,
6–10, 11–16, >16 years). Caseload (number of hospital
stays included in the analyses for each QI, per hospital,
and per year) was also included in the model as a vari-
able at hospital level.
For pneumonia, results were weighted for caseload.
A time lag (±1 year) was introduced to account for the
fact that the effect of AMT funding might have started
before the hospitals received the money (eg, because
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preparation included AM stewardship training) and
might need some time to be fully implemented (eg,
because of possible delays in recruiting an AM specialist).
Statistical model and software
A somewhat abrupt but continuous change in the evolu-
tion of the outcome over time can be modelled by
including a change point in the generalised linear
mixed model (GLMM).17 A GLMM is an extension of a
generalised linear model in which the correlation
between measurements from the same hospital is taken
into account using so-called random effects. Whereas
the outcome is considered to belong to the exponential
family (including the normal and the Bernoulli distribu-
tion), the systematic component of a GLMM is given by:
gðmijÞ ¼ (b0 þ b0i)þ (b1 þ b1i)tij þ b2(tij  CP)þ
þ
XQ
q¼3
bqXqij
where μij is the average outcome for hospital i (i=1, 2,…,
N) at time points tij ( j=1, 2,…, ni), g(.) is a link function
(eg, an identity link or a logit link), N is the total
number of hospitals, ni is the number of observations
from the i-th hospital, tij=1 corresponds to the start of
the study, b0is the ﬁxed intercept, b0i is the hospital-
speciﬁc deviation from intercept b0, b1is the ﬁxed slope,
b1i is the hospital-speciﬁc deviation from slope b1,
xþ ¼ maxðx; 0Þ such that b2 is the global difference in
the linear trend before and after the change point, CP
is a global change point, bq(q=3, 4,…, Q) are the ﬁxed
effects for the explanatory variables Xqij and Q is the
number of explanatory variables. All models were ﬁtted
using SAS V.9.3.
RESULTS
Surgery QI
A total of 325 094 hospitals stays between 1999 and 2010
were available for analyses (90% of the total number of
stays coded APR DRG 302, after exclusion of SoI 3 and
4, stays with infectious diagnoses, and errors in hospital
coding). Median LoS in this population decreased from
15 days in 1999 to 8 days in 2010. Trends in the number
of hospital stays and compliance with the three criteria, as
deﬁned earlier, are shown in table 1. Compliance increased
from 53% of included stays in 1999 to 71% in 2010.
Based on likelihood ratio (LR) tests comparing
models with and without speciﬁc change points, the
change point ‘year of AMT’ was retained in the model
(p<0.0001); the change point ‘year 2001’ was identiﬁed
as statistically signiﬁcant (p<0.0001). All changes were
negative and weak (meaning that compliance increased,
but at a slower pace than before). The ﬁnal model had
a pseudo-R² value of 0.1927. Although R² values for
models on binary outcomes are typically much lower
than for models on continuous outcomes, this indicates
that there is still a lot of unexplained residual variability.
Observed and predicted values for the full model, and
for hospitals according to the year of funding AMT, are
shown in ﬁgure 1.
Pneumonia QI
A total of 327 635 hospitals stays between 1999 and 2010
were available for analyses (95% of the total number of
stays coded APR DRG 139, after exclusions for coding
errors). All had ‘pneumonia’ as an admission diagnosis,
so we assume that the vast majority of patients were
admitted for community-acquired pneumonia. (In
theory, it is possible that some patients were transferred
from another hospital with a hospital-acquired pneumo-
nia.) From 1999 to 2010, median LoS in this population
decreased from 9 to 7 days, percentile 25 for age
decreased from 16 to 11 years. Case fatality decreased in
all four categories of SoI, from 1.6% to 0.4% in less
severe illness (SoI 1), and from 40% to 33% in more
severe illness (SoI 4).
Trends in the number of hospital stays and the QI are
shown in table 2. Between 1999 and 2010, the mean
DDD of AM other than J01C decreased from 96 to 64/
100 days of hospitalisation for pneumonia; the O/P ratio
(all AM) increased from 0.72 to 0.97.
Based on LR tests comparing models with and without
speciﬁc change points, the change point ‘year of AMT’
was not retained in the models for the DDD QI
(p=0.4659), nor for the O/P QI (p: 0.0997). This
means that there was no statistically signiﬁcant change in
slope for these outcomes, that is, the year a hospital
received funding for their AMT.
For the DDD QI, the years 2001 and 2006 were iden-
tiﬁed as statistically signiﬁcant change points
(p<0.0001 and 0.0009, respectively). In 2001, the QI
Table 1 Hospital stays for lower limb orthopaedic
surgery* and compliance with guidelines for surgical
prophylaxis, Belgium, 1999–2010
Year N hospitals
N stays
Stays with
cefazolin, 2–8 g,
no other
antimicrobials
100% N Per cent
1999 110 18 562 9802 53
2000 110 20 559 11 691 57
2001 110 21 790 12 597 58
2002 110 23 254 13 274 57
2003 110 24 606 14 823 60
2004 110 25 917 16 942 65
2005 110 27 756 18 551 67
2006 110 29 267 19 761 68
2007 108 30 727 21 336 69
2008 107 32 708 22 796 70
2009 106 34 256 23 930 70
2010 104 35 692 25 264 71
*APR-DRG 302, severity of illness 1 and 2.
APR-DRG, all-patient-refined diagnosis-related group.
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decreased, and the effect was strong. In 2006, the QI
decreased at a slower pace than before. The adjusted
R² for the ﬁnal model was 0.8072. For the O/P ratio
QI, the year 2001 was not retained in the model
(p=0.9884), while the year 2006 was identiﬁed as a stat-
istically signiﬁcant change point (p=0.0310): the QI
increased, but at a slower pace than before. The
adjusted R² for the ﬁnal model was 0.7559. For these
two pneumonia outcomes, the high adjusted R² indi-
cates that the models perform well in explaining the
variability in the data. The effect of the ‘2006’ change
point on both QIs was weak and of doubtful clinical
signiﬁcance, as shown in ﬁgure 2.
General features of statistical modelling
All 3 QIs showed high heterogeneity: baseline values as
well as changes over time varied widely across hospitals.
Another feature was the complexity of the predicting
models, which involved many parameters, and interac-
tions, rendering interpretation sometimes difﬁcult, so
that the effect of ‘change points’ is better assessed visu-
ally on the ﬁgures presented. Of importance, the intro-
duction of time lags in the models (ie, taking into
account the year before or the year after the ‘change
points’) did not improve the models. A complete
description of the results, interaction terms and esti-
mates is available in the full study report.18
DISCUSSION
Key findings
In 1999, 53% of patients admitted in hospital for major
lower limb orthopaedic surgery received the recom-
mended AM for surgical antibioprophylaxis, with a
dosage in the expected range, and no other AM. This
ﬁgure was 71% in 2010. For patients treated for pneu-
monia over the same period, the mean consumption of
AM other than penicillin decreased from 96 DDD to 64
DDD/100 hospital-days, and the ratio of oral/parenteral
DDD increased from 0.72 to 0.97. There was high het-
erogeneity between hospitals. No positive effect could be
Figure 1 Average observed and predicted (dotted) evolution of compliance with guidelines for surgical antibiotic prophylaxis for
lower limb surgery*, Belgium, 1999–2010. AMT, antimicrobial management teams; APR-DRG, all-patient-refined
diagnosis-related group.
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detected at the national level for these three QIs in rela-
tion to the timing of implementation of the policy. In
2001, the decrease in the pneumonia DDD indicator
was a statistically and most likely clinically signiﬁcant
deviation from expected trends.
Strengths and limitations
To the best of our knowledge, this is the ﬁrst study speciﬁc-
ally evaluating a national policy of implementing and
funding AM stewardship programme at hospital level.
Another country—Scotland—funds AMT in hospitals
since 2008,19 as part of a comprehensive policy to improve
AM prescribing. The Scottish policy as a whole appears to
be successful—but the extent to which the funding of
AMTcontributes to this success remains unknown.20
Its major strengths are an exhaustive patient-based
database including all Belgian hospitals over 12 years.
The fact that the intervention was implemented at differ-
ent times allowed us to compare QIs both within and
between hospitals (hospitals before and after implemen-
tation of the policy, as well as hospitals with and without
the policy); our ﬁne-tuned case-mix adjustment removed
confounding due to differences in the patient popula-
tion. The two APR-DRG studied account for the largest
Figure 2 Average observed and predicted (dotted) evolution of quality indicators for antimicrobial treatment of community-
acquired pneumonia* in hospitals, Belgium, 1999–2010. APR-DRG, all-patient-refined diagnosis-related group; J01C, ATC code,
β-lactam penicillin; DDD: defined daily dose.
Table 2 Hospital stays for simple pneumonia* and quality indicators for antimicrobial treatment, Belgium, 1999–2010
Year N hospitals N stays
Mean DDD/100 patient-days DDD oral/DDD parenteral
J01C Other Total J01C Other Total
1999 112 22 385 66 96 161 0.57 0.84 0.72
2000 112 23 268 67 97 164 0.58 0.87 0.74
2001 112 24 165 70 100 170 0.62 0.91 0.77
2002 112 25 424 75 97 172 0.66 0.81 0.74
2003 112 26 331 83 89 172 0.69 0.83 0.76
2004 112 25 201 91 82 172 0.79 0.82 0.80
2005 112 30 145 97 81 178 0.83 0.93 0.87
2006 112 26 739 99 74 173 0.87 0.96 0.91
2007 110 28 872 99 68 167 0.89 1.04 0.95
2008 110 29 823 101 65 166 0.90 1.02 0.95
2009 109 33 611 102 63 165 0.90 1.11 0.98
2010 107 31 671 106 64 170 0.88 1.12 0.97
*APR-DRG 139.
APR-DRG, all-patient-refined diagnosis-related group; DDD, defined daily dose; J01C, ATC code, β-lactam penicillin; patient-days, only
patients hospitalised for pneumonia.
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number of patients receiving AM in hospitals. The trend
in improvement for the surgery QI is robust, even if true
compliance is less than what we measured, as our QI does
not include timing of AM administration. We used
state-of-the art statistical methods for modelling the
trends of our QI, and acknowledged that change can take
time by introducing time lags in the model (taking into
account one year before, one year after the ‘change
point’); nonetheless, these did not improve the model.
The major limitation of this study is that we only looked
at three QIs for two indications. These QIs do not
measure patient outcomes such as surgical site infection
or mortality (but these are only indirectly related to
appropriate AM prescription, eg, overshooting could also
cure a patient). One QI is questionable. The decreasing
trends in the consumption of DDD other than penicillin
mainly reﬂect a decrease in cephalosporins and macro-
lides which offsets an increase in carbapenems and ﬂuor-
oquinolones. The decrease is also partly explained by a
shift towards broad-spectrum penicillin ( J01CR, or com-
binations, such as amoxicillin—clavulanic acid).18 It is
therefore unclear whether the decrease in this QI indeed
represents a true improvement in quality.
Interpretation
At least two out of three of our QIs describe a true
improvement in AM use for patients admitted to hos-
pital for pneumonia and lower limb surgery between
1999 and 2010 in Belgium; these improvements have
beneﬁted a very large number of patients. Exactly why
this happened is unclear. Although 2001 (a ‘change
point’ for the DDD QI) was the year of a very large
awareness campaign for AM, this campaign targeted
upper respiratory tract infections in the community.
There are several possible explanations for the lack of
association between improvement in the QIs and the
year of implementation of AMT in hospitals. The
selected items for QI, that is, prophylaxis for major limb
orthopaedic surgery and AM therapy in community
acquired pneumonia, are items/topics likely to have
been addressed in the hospital AM policy at different
time points, fully or largely independent from the imple-
mentation of AMT. AMT were not given targets, and
therefore might have chosen other priorities for inter-
ventions than the indications analysed here, despite
these being the indications with the highest volume of
patients receiving AM. (In 2013, however, all AMT in
Belgium conducted audits for antibioprophylaxis in
surgery in which serious gaps were identiﬁed.21) It is
also possible that the earmarked AMT funding was not
always used directly for AMT implementation. A major
shortcoming resides in the absence of data on the actual
use of funding within hospitals, which may not be easily
extracted from the annual AMT activity reports.
Generalisability
The generalisability of our study ﬁnding is limited by the
intrinsic complexity of evaluating the quality of AM use
in hospitals. We investigated only a limited number of
QIs for a limited number of indications: this does not
provide a complete picture of trends in quality of AM
use in Belgian hospitals, and of the effect of implement-
ing and funding AMT in hospitals. This study should
ideally be complemented by other indicators, which
might provide different results. For instance, worrying
trends are observed for hospital use of some AM;
between 1999 and 2010, the use of colistine quadrupled
and the use of carbapenem more than doubled (6–24
DDD, and 118–265, per 10 000 patient-days,
respectively).18
Political commitment for tackling the problem of AM
resistance in general, and improving AM use in hospitals
in particular, has clearly been increasing in the
past decade in Europe, North America and else-
where.7 22–26 Recommendations for strengthening the
legal basis and core funding of antibiotic stewardship
programmes acknowledge the urgent need for building
an evidence base for such policies through good quality
research,7 8 and we believe that this study contributes to
this objective.
CONCLUSIONS
Our study has shown improvement on selected QIs for
AM use in the treatment of pneumonia, and in antibio-
prophylaxis for lower limb orthopaedic surgery in
Belgian hospitals between 1999 and 2010. These
improvements could not be related to a policy of
funding AMT. Changes observed may therefore reﬂect
the more multifactorial and continuous change process
of quality improvement, of which the implementation
and funding of AMT was rather a consequence than a
primary driver.
Our ﬁndings do not question the need for AMT, nor
the need for continuation of AMT funding. Several
recommendations could be made in order to make the
best of the Belgian unique political, and ﬁnancial com-
mitment in that ﬁeld. Transparency in the use of ear-
marked funding for AMT at hospital level could be
improved. Trends of other AM QIs deserve more
research. AMTs in hospitals should beneﬁt from more
guidance in terms of identifying priorities for action.
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